Ii-Key/MHC class II epitope peptides as helper T cell vaccines for cancer and infectious disease

Frontiers in Bioscience

Volumn 11, Issue 1 P.1-446, 2006, Pages 46-58

  Kallinteris, Nikoletta L ^a   Powell, Douglas ^a   Blackwell, Catherine E ^a   Kim, MaryBeth ^a   Lu, Xueqing ^a   Wu, Shuzhen ^a   Humphreys, Robert E ^a   Xu, Minzhen ^a   Von Hofe, Eric ^a  

^a Antigen Express Inc ^*  (United States)

Author keywords

Immune system; Immunity; Immunotherapy; Invariant chain; MHC class II; Review

Indexed keywords

EID: 32844473600     PISSN: 27686701     EISSN: 27686698     Source Type: Journal    
DOI: 10.2741/1779     Document Type: Review

References (72)

1. Elliott W. L., C. J. Stille, L. J. Thomas & R. E. Humphreys: An hypothesis on the binding of an amphipathic, alpha helical sequence in Ii to the desetope of class II antigens. J Immunol 138, 2949-52 (1987)
2. Nguyen Q. V. & R. E. Humphreys: Time course of intracellular associations, processing, and cleavages of Ii forms and class II major histocompatibility complex molecules. J Biol Chem 264, 1631-7 (1989)
3. Nguyen Q. V., W. Knapp & R. E. Humphreys: Inhibition by leupeptin and antipain of the intracellular proteolysis of Ii. Hum Immunol 24, 153-63 (1989)
4. Sorli C. H., P. S. Reisert, W. J. Welch & R. E. Humphreys: Identification of p70 and p80 associations with class II MHC molecules and Ii. Am J Hematol 35, 157-66 (1990)
5. Nguyen Q. V., A. M. Roskey & R. E. Humphreys: Effects of brefeldin A on cleavage of invariant chain to p21 and p10 and the appearance of Ii-freed class II MHC dimers. Mol Immunol 30, 137-44 (1993)
6. Nguyen Q. V., W. Knapp & R. E. Humphreys: Characterization of the invariant chain C-terminus (Glu183-Glu193) epitope which is obscured in processed Ii, MHC alpha,beta trimers. Mol Immunol 30, 1679-84 (1993)
7. Nguyen Q. V., V. E. Reyes & R. E. Humphreys: Structural analysis of invariant chain subsets as a function of their association with MHC class II chains. Arch Biochem Biophys 317, 128-32 (1995)
8. Thomas L. J., Q. V. Nguyen, W. L. Elliott & R. E. Humphreys: Proteolytic cleavage of Ii to p25. J Immunol 140, 2670-4 (1988)
9. Thomas L. J., R. E. Humphreys, W. Knapp & Q. V. Nguyen: Time-dependent cleavage of a high-mannose form of Ii to p25 in an intracellular compartment. Am J Hematol 32, 167-77 (1989)
10. Reyes V. E., S. Lu & R. E. Humphreys: Cathepsin B cleavage of Ii from class II MHC alpha- and beta-chains. J Immunol 146, 3877-80 (1991)
11. Daibata M., M. Xu, R. E. Humphreys & V. E. Reyes: More efficient peptide binding to MHC class II molecules during cathepsin B digestion of Ii than after Ii release. Mol Immunol 31, 255-60 (1994)
12. Lu S., V. E. Reyes, R. A. Lew, J. Anderson, J. Mole, R. E. Humphreys & T. Ciardelli: Role of recurrent hydrophobic residues in catalysis of helix formation by T cell-presented peptides in the presence of lipid vesicles. J Immunol 145, 899-904 (1990)
13. Adams S. & R. E. Humphreys: Invariant chain peptides enhancing or inhibiting the presentation of antigenic peptides by major histocompatibility complex class II molecules. Eur J Immunol 25, 1693-702 (1995)
14. Humphreys R. E., S. Adams, G. Koldzic, B. Nedelescu, E. von Hofe & M. Xu: Increasing the potency of MHC class II-presented epitopes by linkage to Ii-Key peptide. Vaccine 18, 2693-7 (2000)
15. Xu M., G. A. Capraro, M. Daibata, V. E. Reyes & R. E. Humphreys: Cathepsin B cleavage and release of invariant chain from MHC class II molecules follow a staged pattern. Mol Immunol 31, 723-31 (1994)
16. Reyes V. E., M. Daibata, R. Espejo & R. E. Humphreys: Invariant chain dissociation from class II MHC is a catalyst for foreign peptide binding. Ann N Y Acad Sci 730, 338-41 (1994)
17. Vazquez S., C. Thomas, R. A. Lew & R. E. Humphreys: Favored and suppressed patterns of hydrophobia and nonhydrophobic amino acids in protein sequences. Proc Natl Acad Sci U S A 90, 9100-4 (1993)
18. Lu S., T. Ciardelli, V. E. Reyes & R. E. Humphreys: Number and placement of hydrophobic residues in a longitudinal strip governs helix formation of peptides in the presence of lipid vesicles. J Biol Chem 266, 10054-7 (1991)
19. Stern L. J., J. H. Brown, T. S. Jardetzky, J. C. Gorga, R. G. Urban, J. L. Strominger & D. C. Wiley: Crystal structure of the human class II MHC protein HLA-DR1 complexed with an influenza virus peptide. Nature 368, 215-21 (1994)
20. Adams S., F. Albericio, J. Alsina, E. R. Smith & R. E. Humphreys: Biological activity and therapeutic potential of homologs of an Ii peptide which regulates antigenic peptide binding to cell surface MHC class II molecules. Arzneimittelforschung 47, 1069-77 (1997)
21. Ghosh P., M. Amaya, E. Mellins & D. C. Wiley: The structure of an intermediate in class II MHC maturation: CLIP bound to HLA-DR3. Nature 378, 457-62 (1995)
22. Xu M., G. Qiu, Z. Jiang, E. von Hofe & R. E. Humphreys: Genetic modulation of tumor antigen presentation. Trends Biotechnol 18, 167-72 (2000)
23. Kallinteris N. L., X. Lu, S. Wu, H. Hu, Y. Li, J. V. Gulfo, R. E. Humphreys & M. Xu: Ii-Key/MHC class II epitope hybrid peptide vaccines for HIV. Vaccine 21, 4128-32 (2003)
24. Gillogly M. E., N. L. Kallinteris, M. Xu, J. V. Gulfo, R. E. Humphreys & J. L. Murray: Ii-Key/HER-2/neu MHC class-II antigenic epitope vaccine peptide for breast cancer. Cancer Immunol Immunother 53, 490-6 (2004)
25. Xu, M., J. Li, J. V. Gulfo, E. Von Hofe & R. E. Humphreys: MHC class II allosteric site drugs: new immunotherapeutics for malignant, infectious and autoimmune diseases. Scand J Immunol 54, 39-44 (2001)
26. Kropshofer H., A. B. Vogt, L. J. Stern & G. J. Hammerling: Self-release of CLIP in peptide loading of HLA-DR molecules. Science 270, 1357-9 (1995)
27. Rammensee H. G., T. Friede & S. Stevanoviic: MHC ligands and peptide motifs: first listing. Immunogenetics 41, 178-228 (1995)
28. Larch, M. & D. C. Wraith: Peptide-based therapeutic vaccines for allergic and autoimmune diseases. Nat Med 11, S69-76 (2005)
29. Touloukian C. E., W. W. Leitner, S. L. Topalian, Y. F. Li, P. F. Robbins, S. A. Rosenberg & N. P. Restifo: Identification of a MHC class II-restricted human gp100 epitope using DR4-IE transgenic mice. J Immunol 164, 3535-42 (2000)
30. Kobayashi H., J. Lu & E. Celis: Identification of helper T-cell epitopes that encompass or lie proximal to cytotoxic T-cell epitopes in the gp100 melanoma tumor antigen. Cancer Res 61, 7577-84 (2001)
31. Cochlovius B., M. Stassar, O. Christ, L. Raddrizzani, J. Hammer, I. Mytilineos & M. Zoller: In vitro and in vivo induction of a Th cell response toward peptides of the melanoma-associated glycoprotein 100 protein selected by the TEPITOPE program. J Immunol 165, 4731-41 (2000)
32. Kierstead L. S., E. Ranieri, W. Olson, V. Brusic, J. Sidney, A. Sette, Y. L. Kasamon, C. L. Slingluff, Jr., J. M. Kirkwood & W. J. Storkus: gp100/pmel17 and tyrosinase encode multiple epitopes recognized by Th1-type CD4+T cells. Br J Cancer 85, 1738-45 (2001)
33. Cormier J. N., Y. M. Hijazi, A. Abati, P. Fetsch, M. Bettinotti, S. M. Steinberg, S. A. Rosenberg & F. M. Marincola: Heterogeneous expression of melanoma-associated antigens and HLA-A2 in metastatic melanoma in vivo. Int J Cancer 75, 517-24 (1998)
34. Kawakami Y., S. Eliyahu, C. H. Delgado, P. F. Robbins, K. Sakaguchi, E. Appella, J. R. Yannelli, G. J. Adema, T. Miki & S. A. Rosenberg: Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection. Proc Natl Acad Sci U S A 91, 6458-62 (1994)
35. Phan G. Q., C. E. Touloukian, J. C. Yang, N. P. Restifo, R. M. Sherry, P. Hwu, S. L. Topalian, D. J. Schwartzentruber, C. A. Seipp, L. J. Freezer, K. E. Morton, S. A. Mavroukakis, D. E. White & S. A. Rosenberg: Immunization of patients with metastatic melanoma using both class I- and class II-restricted peptides from melanoma-associated antigens. J Immunother 26, 349-56 (2003)
36. Sant'Angelo D. B., E. Robinson, C. A. Janeway, Jr. & L. K. Denzin: Recognition of core and flanking amino acids of MHC class II-bound peptides by the T cell receptor. Eur J Immunol 32, 2510-20 (2002)
37. Ito K., H. J. Bian, M. Molina, J. Han, J. Magram, E. Saar, C. Belunis, D. R. Bolin, R. Arceo, R. Campbell, F. Falcioni, D. Vidovic, J. Hammer & Z. A. Nagy: HLA-DR4-IE chimeric class II transgenic, murine class II-deficient mice are susceptible to experimental allergic encephalomyelitis. J Exp Med 183, 2635-44 (1996)
38. Disis M. L., T. A. Gooley, K. Rinn, D. Davis, M. Piepkorn, M. A. Cheever, K. L. Knutson & K. Schiffman: Generation of T-cell immunity to the HER-2/neu protein after active immunization with HER-2/neu peptide-based vaccines. J Clin Oncol 20, 2624-32 (2002)
39. Kuerer H. M., G. E. Peoples, A. A. Sahin, J. L. Murray, S. E. Singletary, A. Castilleja, K. K. Hunt, D. M. Gershenson & C. G. Ioannides: Axillary lymph node cellular immune response to HER-2/neu peptides in patients with carcinoma of the breast. J Interferon Cytokine Res 22, 583-92 (2002)
40. Celis E.: Getting peptide vaccines to work: just a matter of quality control? J Clin Invest 110, 1765-8 (2002)
41. Pardoll D. M. & S. L. Topalian: The role of CD4+ T cell responses in antitumor immunity. Curr Opin Immunol 10, 588-94 (1998)
42. Wolchok J. D. & P. O. Livingston: Vaccines for melanoma: translating basic immunology into new therapies. Lancet Oncol 2, 205-11 (2001)
43. Goel N., D. H. Zimmerman & K. S. Rosenthal: Ligand epitope antigen presentation system vaccines against herpes simplex virus. Front Biosci 10, 966-74 (2005)
44. Rajnavolgyi E. & A. Lanyi: Role of CD4+ T lymphocytes in antitumor immunity. Adv Cancer Res 87, 195-249 (2003)
45. Velders M. P., M. A. Markiewicz, G. L. Eiben & W. M. Kast: CD4+ T cell matters in tumor immunity. Int Rev Immunol 22, 113-40 (2003)
46. Hung K., R. Hayashi, A. Lafond-Walker, C. Lowenstein, D. Pardoll & H. Levitsky: The central role of CD4 (+) T cells in the antitumor immune response. J Exp Med 188, 2357-68 (1998)
47. Ridge J. P., F. Di Rosa & P. Matzinger: A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell. Nature 393, 474-8 (1998)
48. Toes R. E., F. Ossendorp, R. Offringa & C. J. Melief: CD4 T cells and their role in antitumor immune responses. J Exp Med 189, 753-6 (1999)
49. Dudley M. E., J. R. Wunderlich, P. F. Robbins, J. C. Yang, P. Hwu, D. J. Schwartzentruber, S. L. Topalian, R. Sherry, N. P. Restifo, A. M. Hubicki, M. R. Robinson, M. Raffeld, P. Duray, C. A. Seipp, L. Rogers-Freezer, K. E. Morton, S. A. Mavroukakis, D. E. White & S. A. Rosenberg: Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 298, 850-4 (2002)
50. Rosenberg S. A., J. C. Yang & N. P. Restifo: Cancer immunotherapy: moving beyond current vaccines. Nat Med 10, 909-15 (2004)
51. Dudley M. E., J. R. Wunderlich, J. C. Yang, R. M. Sherry, S. L. Topalian, N. P. Restifo, R. E. Royal, U. Kammula, D. E. White, S. A. Mavroukakis, L. J. Rogers, G. J. Gracia, S. A. Jones, D. P. Mangiameli, M. M. Pelletier, J. Gea-Banacloche, M. R. Robinson, D. M. Berman, A. C. Filie, A. Abati & S. A. Rosenberg: Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol 23, 2346-57 (2005)
52. Fisk B., T. L. Blevins, J. T. Wharton & C. G. Ioannides: Identification of an immunodominant peptide of HER-2/neu protooncogene recognized by ovarian tumor-specific cytotoxic T lymphocyte lines. J Exp Med 181, 2109-17 (1995)
53. Scardino A., P. Alves, D. A. Gross, S. Tourdot, S. Graff-Dubois, E. Angevin, H. Firat, S. Chouaib, F. Lemonnier, L. M. Nadler, A. A. Cardoso & K. Kosmatopoulos: Identification of HER-2/neu immunogenic epitopes presented by renal cell carcinoma and other human epithelial tumors. Eur J Immunol 31, 3261-70 (2001)
54. Rongcun Y., F. Salazar-Onfray, J. Charo, K. J. Malmberg, K. Evrin, H. Maes, K. Kono, C. Hising, M. Petersson, O. Larsson, L. Lan, E. Appella, A. Sette, E. Celis & R. Kiessling: Identification of new HER2/neu-derived peptide epitopes that can elicit specific CTL against autologous and allogeneic carcinomas and melanomas. J Immunol 163, 1037-44 (1999)
55. Brossart P., G. Stuhler, T. Flad, S. Stevanovic, H. G. Rammensee, L. Kanz & W. Brugger: Her-2/neu-derived peptides are tumor-associated antigens expressed by human renal cell and colon carcinoma lines and are recognized by in vitro induced specific cytotoxic T lymphocytes. Cancer Res 58, 732-6 (1998)
56. Seliger B., Y. Rongcun, D. Atkins, S. Hammers, C. Huber, S. Storkel & R. Kiessling: HER-2/neu is expressed in human renal cell carcinoma at heterogeneous levels independently of tumor grading and staging and can be recognized by HLA-A2.1-restricted cytotoxic T lymphocytes. Int J Cancer 87, 349-59 (2000)
57. Zaks T. Z. & S. A. Rosenberg: Immunization with a peptide epitope (p369-377) from HER-2/neu leads to peptide-specific cytotoxic T lymphocytes that fail to recognize HER-2/neu+ tumors. Cancer Res 58, 4902-8 (1998)
58. Murray J. L., D. Przepiorka & C. G. Ioannides: Clinical trials of HER-2/neu-specific vaccines. Semin Oncol 27, 71-5; discussion 92-100 (2000)
59. Knutson K. L., K. Schiffman, M. A. Cheever & M. L. Disis: Immunization of cancer patients with a HER-2/neu, HLA-A2 peptide, p369-377, results in short-lived peptide-specific immunity. Clin Cancer Res 8, 1014-8 (2002)
60. Murray J. L., M. E. Gillogly, D. Przepiorka, H. Brewer, N. K. Ibrahim, D. J. Booser, G. N. Hortobagyi, A. P. Kudelka, K. H. Grabstein, M. A. Cheever & C. G. Ioannides: Toxicity, immunogenicity, and induction of E75-specific tumor-lytic CTLs by HER-2 peptide E75 (369-377) combined with granulocyte macrophage colony-stimulating factor in HLA-A2+ patients with metastatic breast and ovarian cancer. Clin Cancer Res 8, 3407-18 (2002)
61. Baxevanis C. N., P. A. Sotiropoulou, N. N. Sotiriadou & M. Papamichail: Immunobiology of HER-2/neu oncoprotein and its potential application in cancer immunotherapy. Cancer Immunol Immunother 53, 166-75 (2004)
62. Brossart P., S. Wirths, G. Stuhler, V. L. Reichardt, L. Kanz & W. Brugger: Induction of cytotoxic T-lymphocyte responses in vivo after vaccinations with peptide-pulsed dendritic cells. Blood 96, 3102-8 (2000)
63. Dudley M. E., J. Wunderlich, M. I. Nishimura, D. Yu, J. C. Yang, S. L. Topalian, D. J. Schwartzentruber, P. Hwu, F. M. Marincola, R. Sherry, S. F. Leitman & S. A. Rosenberg: Adoptive transfer of cloned melanoma-reactive T lymphocytes for the treatment of patients with metastatic melanoma. J Immunother 24, 363-73 (2001)
64. Halder T., G. Pawelec, A. F. Kirkin, J. Zeuthen, H. E. Meyer, L. Kun & H. Kalbacher: Isolation of novel HLA-DR restricted potential tumor-associated antigens from the melanoma cell line FM3. Cancer Res 57, 3238-44 (1997)
65. Knutson K. L., K. Schiffman & M. L. Disis: Immunization with a HER-2/neu helper peptide vaccine generates HER-2/neu CD8 T-cell immunity in cancer patients. J Clin Invest 107, 477-84 (2001)
66. Talebi T. & J. S. Weber: Peptide vaccine trials for melanoma: preclinical background and clinical results. Semin Cancer Biol 13, 431-8 (2003)
67. Parmiani G., C. Castelli, P. Dalerba, R. Mortarini, L. Rivoltini, F. M. Marincola & A. Anichini: Cancer immunotherapy with peptide-based vaccines: what have we achieved? Where are we going? J Natl Cancer Inst 94, 805-18 (2002)
68. Yang S., G. P. Linette, S. Longerich & F. G. Haluska: Antimelanoma activity of CTL generated from peripheral blood mononuclear cells after stimulation with autologous dendritic cells pulsed with melanoma gp100 peptide G209-2M is correlated to TCR avidity. J Immunol 169, 531-9 (2002)
69. Parkhurst M. R., C. DePan, J. P. Riley, S. A. Rosenberg & S. Shu: Hybrids of dendritic cells and tumor cells generated by electrofusion simultaneously present immunodominant epitopes from multiple human tumor-associated antigens in the context of MHC class I and class II molecules. J Immunol 170, 5317-25 (2003)
70. Paczesny S., J. Banchereau, K. M. Wittkowski, G. Saracino, J. Fay & A. K. Palucka: Expansion of melanoma-specific cytolytic CD8+ T cell precursors in patients with metastatic melanoma vaccinated with CD34+ progenitor-derived dendritic cells. J Exp Med 199, 1503-11 (2004)
71. Liao X., Y. Li, C. Bonini, S. Nair, E. Gilboa, P. D. Greenberg & C. Yee: Transfection of RNA encoding tumor antigens following maturation of dendritic cells leads to prolonged presentation of antigen and the generation of high-affinity tumor-reactive cytotoxic T lymphocytes. Mol Ther 9, 757-64 (2004)
72. Rakhmilevich A. L., M. Imboden, Z. Hao, M. D. Macklin, T. Roberts, K. M. Wright, M. R. Albertini, N. S. Yang & P. M. Sondel: Effective particle-mediated vaccination against mouse melanoma by coadministration of plasmid DNA encoding Gp100 and granulocyte-macrophage colony-stimulating factor. Clin Cancer Res 7, 952-61 (2001)